Adicet Bio, Inc. (ACET) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0070022076
Adicet Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -122.11 m USD |
| EBIT | -116.77 m USD |
| Net income | -116.80 m USD |
| Diluted EPS – continuing operations | -16.95 USD |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
More stocks
- MIND TECHNOLOGY, INC (MIND)
- MicroCloud Hologram Inc. (HOLO)
- Amicorp FS (UK) PLC (AMIF.L)
- RADNOSTIX INC (INIS)
- AURA SYSTEMS INC (AUSI)
- Edesa Biotech, Inc. (EDSA)
- AMERICAN VANGUARD CORP (AVD)
- Metagenomi Therapeutics, Inc. (MGX)
- Xos, Inc. (XOS)
- Mono Next Public Company Limited (MONO.BK)
- ATLANTIC AMERICAN CORP (AAME)
- Tonix Pharmaceuticals Holding Corp. (TNXP)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.